Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02415153 · ClinicalTrials.gov registry record · Phase 1
Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT02415153: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT02415153 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 29 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02415153, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This phase I trial studies the side effects and best dose of pomalidomide in treating younger patients with tumors of the brain or spine (central nervous system) that have come back or are continuing to grow. Pomalidomide may interfere with the ability of tumor cells to grow and spread and may also stimulate the immune system to kill tumor cells.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Pomalidomide
- OTHER Pharmacological Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-07-14 |
| Est. Completion | 2020-05-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02415153
The ClinicalTrials.gov registry entry for NCT02415153 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02415153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02415153 about?
NCT02415153 is a clinical study titled "Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors". This phase I trial studies the side effects and best dose of pomalidomide in treating younger patients with tumors of the brain or spine (central nervous system) that have come back or are continuing to grow. Pomalidomide may interfere with the ability of tumor cells to grow and spread and may also ...
What is the current status of trial NCT02415153?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-07-14. Estimated completion is 2020-05-27.
What interventions are being tested in trial NCT02415153?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Pomalidomide (DRUG), Pharmacological Study (OTHER).
Who is sponsoring clinical trial NCT02415153?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.